Abstract
MMP-7 is the smallest metalloproteinase. Its unregulated activities and existence in serum are recently known to be tightly related with life-threatening disease such as cardiac disease and several cancers. The protein production is thought to be useful for its characterization and antibody generation. Although many attempts at bacterial expressions have been conducted, they were recovered as insoluble and inactive protein. In this study, after soluble expression, singlestep purification and conversion to active protease, it was applied for the screening secretory metalloproteinase inhibitors in conditioned media of human cancer cells.
Keywords: MMP-7/matrilysin, matrix metalloproteinase, GST fusion, metalloproteinase inhibitor, soluble expression in E. coli, reverse-zymography
Protein & Peptide Letters
Title: Production of Active MMP7 in E. coli and Its Application for Metalloproteinase Inhibitors Screening
Volume: 17 Issue: 5
Author(s): H. Katsuno, R. Shirakawa, K. Miyazaki, Y. Ozeki and H. Yasumitsu
Affiliation:
Keywords: MMP-7/matrilysin, matrix metalloproteinase, GST fusion, metalloproteinase inhibitor, soluble expression in E. coli, reverse-zymography
Abstract: MMP-7 is the smallest metalloproteinase. Its unregulated activities and existence in serum are recently known to be tightly related with life-threatening disease such as cardiac disease and several cancers. The protein production is thought to be useful for its characterization and antibody generation. Although many attempts at bacterial expressions have been conducted, they were recovered as insoluble and inactive protein. In this study, after soluble expression, singlestep purification and conversion to active protease, it was applied for the screening secretory metalloproteinase inhibitors in conditioned media of human cancer cells.
Export Options
About this article
Cite this article as:
Katsuno H., Shirakawa R., Miyazaki K., Ozeki Y. and Yasumitsu H., Production of Active MMP7 in E. coli and Its Application for Metalloproteinase Inhibitors Screening, Protein & Peptide Letters 2010; 17 (5) . https://dx.doi.org/10.2174/092986610791112648
DOI https://dx.doi.org/10.2174/092986610791112648 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
Current Drug Targets Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Recent Applications of Doebner, Doebner-von Miller and Knoevenagel-Doebner Reactions in Organic Syntheses
Current Organic Synthesis Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews D-amino Acids as Novel Blood-based Biomarkers
Current Medicinal Chemistry Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Human Saliva Metabolome for Oral Lichen Planus Biomarker Identification
Recent Patents on Anti-Cancer Drug Discovery Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates
Current Pharmaceutical Design Patents in Cancer Stem Cells
Recent Patents on Biomarkers Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations
Current Medicinal Chemistry